Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Alphabets quarterly earnings miss and higher AI infrastructure spendingraising concerns about negative free cash flow and slower Search and ad growthare driving the selloff discussion. Traders are divided between those worried about spending and pressure on Search monetization and those calling the reaction excessive, pointing to strong Cloud growth and investment-related losses that they view as non-operational.

Iovances announcement of positive Phase 2 lifileucel results in previously treated metastatic non-small-cell lung cancer has driven attention, with traders focused on the therapys potential beyond melanoma. The community is largely enthusiastic about the larger market opportunity, while some remain cautious about the detailed results, the regulatory path, and a possible sell-the-news reaction.

Alphabets quarterly results missed expectations, and heavy AI infrastructure spending, weaker cash flow, and slowing Search and ad growth have raised concerns about whether AI investments can generate adequate returns. Traders are split between viewing the selloff as an overreactionpointing to strong Cloud growthand fearing pressure on profits and Search monetization.

Microsofts quarterly earnings beat expectations, with Azure growth accelerating and AI demand supporting the cloud outlook; capital spending came in below estimates, partly because of delayed capacity deliveries. Traders largely welcomed the results and compared them favorably with Alphabets report, though some questioned cash-flow pressure and the durability of the initial share gains.

SELLAS said its Phase 3 REGAL AML trial reached the 80th event, triggering final analysis, with preliminary topline results expected this quarter; the update disclosed no survival benefit. Traders debated the sharp selloff, with bulls treating it as a buying opportunity ahead of the binary readout and bears emphasizing the risk that the trial may fail.

Reports that Marvell is in advanced talks to acquire Lumentum dominate discussion, though no deal is final. Traders debate whether the move would strengthen Marvells AI-data-center optics business or burden shareholders with costly financing and dilution.

Intellia shares are drawing attention alongside other gene-editing stocks after the FDA proposed a pathway that could streamline development of personalized gene-editing treatments. Traders are debating how directly the draft guidance benefits NTLA, while also focusing on lonvo-zs regulatory path and the stocks sharp volatility.

ServiceNows quarterly results triggered a sharp selloff as an earnings miss and a slower outlook for near-term contracted revenue growth overshadowed stronger revenue and raised AI targets. Traders are split between viewing the reaction as an overdone reset and worrying that slowing growth, high expectations, and AI disruption threaten the software business.

A nonbinding take-private proposal from a Trian-led investor group has put Wendys in focus, with an independent board committee evaluating the offer. Traders largely call it too low and debate whether the board will reject or negotiate for more, while some speculate about competing bids and a short squeeze.

Broadcoms AI-chip supply and financing arrangements tied to Anthropic, alongside the companys IPO filing and analyst upgrades, have renewed focus on its AI demand outlook. Bulls see the deal as added visibility for custom-chip demand, while skeptics question the financing structure and Broadcoms exposure to equipment values; traders also debate whether the recent rebound can overcome the stocks prolonged weakness.